Literature DB >> 29630521

Prognostic and predictive value of long non-coding RNA GAS5 and mircoRNA-221 in colorectal cancer and their effects on colorectal cancer cell proliferation, migration and invasion.

Lin Liu, Tao Meng, Xin-Hui Yang, Parhat Sayim, Cheng Lei, Bo Jin, Lei Ge, Hai-Jiang Wang.   

Abstract

BACKGROUND: LncRNA and microRNA play an important role in the development of human cancers; they can act as a tumor suppressor gene or an oncogene. LncRNA GAS5, originating from the separation from tumor suppressor gene cDNA subtractive library, is considered as an oncogene in several kinds of cancers. The expression of miR-221 affects tumorigenesis, invasion and metastasis in multiple types of human cancers. However, there's very little information on the role LncRNA GAS5 and miR-221 play in CRC. Therefore, we conducted this study in order to analyze the association of GAS5 and miR-221 with the prognosis of CRC and preliminary study was done on proliferation, metastasis and invasion of CRC cells. In the present study, we demonstrate the predictive value of long non-coding RNA GAS5 (lncRNA GAS5) and mircoRNA-221 (miR-221) in the prognosis of colorectal cancer (CRC) and their effects on CRC cell proliferation, migration and invasion.
METHODS: One hundred and fifty-eight cases with CRC patients and 173 cases of healthy subjects that with no abnormalities, who've been diagnosed through colonoscopy between January 2012 and January 2014 were selected for the study. After the clinicopathological data of the subjects, tissue, plasma and exosomes were collected, lncRNA GAS5 and miR-221 expressions in tissues, plasma and exosomes were measured by reverse transcription quantitative polymerase chain reaction (RT-qPCR). The diagnostic values of lncRNA GAS5 and miR-221 expression in tissues, plasma and exosomes in patients with CRC were analyzed using receiver operating characteristic curve (ROC). Lentiviral vector was constructed for the overexpression of lncRNA GAS5, and SW480 cell line was used for the transfection of the experiment and assigned into an empty vector and GAS5 groups. The cell proliferation, migration and invasion were tested using a cell counting kit-8 assay and Transwell assay respectively.
RESULTS: The results revealed that LncRNA GAS5 was upregulated while the miR-221 was downregulated in the tissues, plasma and exosomes of patients with CRC. The results of ROC showed that the expressions of both lncRNA GAS5 and miR-221 in the tissues, plasma and exosomes had diagnostic value in CRC. While the LncRNA GAS5 expression in tissues, plasma and exosomes were associated with the tumor node metastasis (TNM) stage, Dukes stage, lymph node metastasis (LNM), local recurrence rate and distant metastasis rate, the MiR-221 expression in tissues, plasma and exosomes were associated with tumor size, TNM stage, Dukes stage, LNM, local recurrence rate and distant metastasis rate. LncRNA GAS5 and miR-221 expression in tissues, plasma and exosomes were found to be independent prognostic factors for CRC. Following the overexpression of GAS5, the GAS5 expressions was up-regulated and miR-221 expression was down-regulated; the rate of cell proliferation, migration and invasion were decreased.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29630521     DOI: 10.3233/CBM-171011

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  37 in total

Review 1.  Alternating exosomes and their mimetics as an emergent strategy for targeted cancer therapy.

Authors:  Lokesh Chandra Mishra; Utkarsh Pandey; Abhikarsh Gupta; Jyotsna Gupta; Monal Sharma; Gauri Mishra
Journal:  Front Mol Biosci       Date:  2022-08-10

Review 2.  Small Extracellular Vesicles: Key Forces Mediating the Development and Metastasis of Colorectal Cancer.

Authors:  Wenjie Zhang; Xiaoxue Hu; Zhengting Jiang
Journal:  Cells       Date:  2022-05-29       Impact factor: 7.666

Review 3.  Research updates on the clinical implication of long noncoding RNA in digestive system cancers and chemoresistance.

Authors:  Xinzhi Miao; Fang Wang; Tianyun Wang; Siti Razila Abdul Razak; Muhammad Amir Yunus; Ida Shazrina Ismail
Journal:  3 Biotech       Date:  2021-09-01       Impact factor: 2.893

Review 4.  Role of exosomal non-coding RNAs from tumor cells and tumor-associated macrophages in the tumor microenvironment.

Authors:  Zijie Xu; Yi Chen; Ling Ma; Yizhang Chen; Jingya Liu; Yuchen Guo; Ting Yu; Lianghui Zhang; Lingjun Zhu; Yongqian Shu
Journal:  Mol Ther       Date:  2022-04-09       Impact factor: 12.910

5.  High expression of tumor susceptibility gene 101 (TSG101) is associated with more aggressive behavior in colorectal carcinoma.

Authors:  Elmira Gheytanchi; Leili Saeednejad Zanjani; Roya Ghods; Maryam Abolhasani; Marzieh Shahin; Somayeh Vafaei; Marzieh Naseri; Fahimeh Fattahi; Zahra Madjd
Journal:  J Cancer Res Clin Oncol       Date:  2021-02-22       Impact factor: 4.553

Review 6.  The functional roles of exosomal long non-coding RNAs in cancer.

Authors:  Man Wang; Li Zhou; Fei Yu; Yinfeng Zhang; Peifeng Li; Kun Wang
Journal:  Cell Mol Life Sci       Date:  2019-01-25       Impact factor: 9.261

Review 7.  Genome-wide analysis reveals the emerging roles of long non-coding RNAs in cancer.

Authors:  Xiaoxia Ren
Journal:  Oncol Lett       Date:  2019-11-22       Impact factor: 2.967

Review 8.  From inflammatory bowel disease to colorectal cancer: what's the role of miRNAs?

Authors:  Mostafa Vaghari-Tabari; Niloufar Targhazeh; Soheila Moein; Durdi Qujeq; Forough Alemi; Maryam Majidina; Simin Younesi; Zatollah Asemi; Bahman Yousefi
Journal:  Cancer Cell Int       Date:  2022-04-11       Impact factor: 5.722

Review 9.  Novel biomarkers for the diagnosis and prognosis of colorectal cancer.

Authors:  Hyung-Hoon Oh; Young-Eun Joo
Journal:  Intest Res       Date:  2019-11-30

Review 10.  Circulating non-coding RNAs as new biomarkers and novel therapeutic targets in colorectal cancer.

Authors:  L Yang; X Zhang; G Hu
Journal:  Clin Transl Oncol       Date:  2021-07-18       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.